JAGX · Insider Trading
Jaguar Health, Inc.
Every open-market purchase and sale reported by JAGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | John Micek | Director | A | +7,377 | — |
| 2026-01-21 | Steven R. King | See Remarks | A | +11,740 | — |
| 2026-01-21 | Lisa A Conte | See Remarks | A | +28,592 | — |
| 2026-01-21 | Jonathan S. Wolin | See Remarks | A | +11,740 | — |
| 2025-12-15 | Jonathan B. Siegel | Director | A | +7,377 | — |
| 2025-12-15 | Anula Jayasuriya | Director | A | +5,870 | — |
| 2025-12-15 | Carol R. Lizak | Chief Financial Officer | A | +11,740 | — |
| 2025-12-15 | Pravin R Chaturvedi | Chief Scientific Officer | A | +11,740 | — |
| 2025-12-15 | James J Bochnowski | Director | A | +6,363 | — |
| 2025-06-26 | Steven R. King | See Remarks | MIXED | +7,489 deriv. | — |
| 2025-06-26 | James J Bochnowski | Director | MIXED | +56,172 deriv. | — |
| 2025-06-26 | Jonathan S. Wolin | See Remarks | MIXED | +18,724 deriv. | — |
| 2025-06-26 | John Micek | Director | MIXED | +18,724 deriv. | — |
| 2025-06-26 | Jonathan B. Siegel | Director | MIXED | +18,724 deriv. | — |
| 2025-06-26 | Lisa A Conte | CEO and President | MIXED | +18,724 deriv. | — |
| 2025-06-26 | Pravin R Chaturvedi | Chief Scientific Officer | MIXED | +7,489 deriv. | — |
| 2025-05-20 | Lisa A Conte | CEO and President | M | +2 | — |
| 2025-05-20 | Steven R. King | See Remarks | M | +1 | — |
| 2025-04-02 | Carol R. Lizak | Chief Financial Officer | Buy | +10,800 deriv. | — |
| 2025-04-02 | Steven R. King | See Remarks | Buy | +7,200 deriv. | — |
| 2025-04-02 | Pravin R Chaturvedi | Chief Scientific Officer | Buy | +7,200 deriv. | — |
| 2025-04-02 | John Micek | Director | Buy | +18,000 deriv. | — |
| 2025-04-02 | Lisa A Conte | CEO and President | Buy | +18,000 deriv. | — |
| 2025-04-02 | James J Bochnowski | Director | Buy | +54,004 deriv. | — |
| 2025-04-02 | Jonathan S. Wolin | See Remarks | Buy | +18,000 deriv. | — |
| 2025-04-02 | Jonathan B. Siegel | Director | Buy | +18,000 deriv. | — |
| 2024-10-10 | John Micek | Director | A | +26,500 deriv. | — |
| 2024-10-10 | Anula Jayasuriya | Director | A | +21,000 deriv. | — |
| 2024-10-10 | Pravin R Chaturvedi | Chief Scientific Officer | A | +4,922 | — |
| 2024-10-10 | James J Bochnowski | Director | A | +23,200 deriv. | — |
| 2024-10-10 | Jonathan B. Siegel | Director | A | +26,500 deriv. | — |
| 2024-10-10 | Steven R. King | See Remarks | A | +4,922 | — |
| 2024-10-10 | Carol R. Lizak | Chief Financial Officer | A | +4,280 | — |
| 2024-10-10 | Lisa A Conte | See Remarks | A | +16,503 | — |
| 2024-10-10 | Jonathan S. Wolin | See Remarks | A | +4,922 | — |
| 2024-05-21 | Steven R. King | See Remarks | M | +612 | — |
| 2024-05-21 | Lisa A Conte | CEO and President | M | +2,695 | — |
| 2024-05-21 | Carol R. Lizak | Chief Financial Officer | M | +431 | — |
| 2024-05-21 | Jonathan S. Wolin | Chief of Staff, CCO & GC | M | +871 | — |
| 2024-05-21 | Pravin R Chaturvedi | Chief Scientific Officer | M | +871 | — |
| 2024-04-17 | Jonathan S. Wolin | Chief of Staff, CCO & GC | M | +89 | — |
| 2024-04-17 | Lisa A Conte | CEO and President | M | +600 | — |
| 2024-04-17 | Pravin R Chaturvedi | Chief Scientific Officer | M | +134 | — |
| 2024-04-17 | Carol R. Lizak | Chief Financial Officer | M | +60 | — |
| 2024-04-17 | Steven R. King | See Remarks | M | +178 | — |
| 2023-08-14 | Jonathan S. Wolin | Chief of Staff, CCO & GC | A | +196,628 | — |
| 2023-08-14 | Carol R. Lizak | Chief Financial Officer | A | +142,088 | — |
| 2023-08-14 | James J Bochnowski | Director | A | +76,613 | — |
| 2023-08-14 | John Micek | Director | A | +68,568 | — |
| 2023-08-14 | Steven R. King | see remarks | A | +159,168 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Lisa A Conte | See Remarks | 56 | $133 |
| Steven R. King | See Remarks | 23 | $55 |
| Carol R. Lizak | Chief Financial Officer | 23 | $55 |
| Jonathan S. Wolin | See Remarks | 23 | $55 |
| Pravin R Chaturvedi | Chief Scientific Officer | 23 | $55 |
| John Micek | Director | 14 | $33 |
| Jonathan B. Siegel | Director | 14 | $33 |
| James J Bochnowski | Director | 12 | $28 |
| Anula Jayasuriya | Director | 11 | $26 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the JAGX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.